SEOUL, Korea & JACKSONVILLE, Fla.--(BUSINESS WIRE)-- South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery ...
(RTTNews) - SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, 'GBP410' also known as SP0202, evaluating ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The $5.8 billion project will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results